Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside

Journal of Clinical Oncology

Volumn 12, Issue 5, 1994, Pages 1036-1044

  Livingston, Philip O ^a   Wong, George Y C ^b   Adluri, Sucharita ^b   Tao, Yue ^b   Padavan, Maureen ^b   Parente, Rosemary ^b   Hanlon, Christine ^b   Calves, Michele Jones ^b   Helling, Friedhelm ^b   Ritter, Gerd ^b   Oettgen, Herbert F ^b   Old, Lloyd J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM2; IMMUNOGLOBULIN M;

ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOSTIMULATION; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MELANOMA; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0028205790     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.5.1036     Document Type: Article

References (37)

1. Boring CC, Squires TS, Tong T: Cancer statistics. 42:19-38, 1992
2. Balch CM, Smalley RV, Bartolucci AA, et al: A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): Prognostic factors analysis and preliminary results of immunotherapy. Cancer 49:1079-1084, 1982
3. Coit DG, Rogatko A, Brennan MF: Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. Ann Surg 214:627-636, 1991
4. Steffens TA, Livingston PO: The status of adjuvant therapy of melanoma. Surg Oncol Clin North Am 1:307-333, 1992
5. Oettgen HF, Livingston PO, Old LJ: Melanoma, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1991, pp 682-701
6. Livingston PO: Construction of cancer vaccines with carbohydrates and protein (peptide) tumor antigens. Curr Opin Immunol 4:624-629, 1992
7. Tai T, Cahan LD, Tsuchida T, et al: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1985
8. Livingston PO, Natoli EJ Jr, Calves MJ, et al: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911-2915, 1987
9. Livingston PO, Ritter G, Srivastava P, et al: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050, 1989
10. Greenspan EM: Is BCG an "orphan" drug suffering from chemotherapists' overkill? Cancer Invest 4:81-92, 1986
11. Awwad M, North RJ: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: A consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 49:1649-1654, 1989
12. Mokyr MB, Dray S: Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 43:3112-3119, 1983
13. Natoli EJ Jr, Livingston PO, Cordon-Cardo C, et al: A murine monoclonal antibody detecting N-acetyl and N-glycolyl GM2: Characterization of cell surface reactivity. Cancer Res 46:4116-4120, 1986
14. Cahan LD, Irie RF, Singh R, et al: Identification of a human neuroectodermal tumor antigen (OFA-I-2) as gangliside GD2. Proc Natl Acad Sci USA 79:7629-7633, 1982
15. Livingston PO, DeLeo AB, Jones M, et al: Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: Pretreatment with cyclophosphamide is most effective. J Immunol 131:2601-2605, 1983
16. Livingston PO, Cunningham-Rundles S, Marfleet G, et al: Inhibition of suppressor cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 6:392-403, 1987
17. Pinsky CM, El Domeiri A, Caron AS, et al: Delayed hypersensitivity reactions in patients with cancer. Recent Results Cancer Res 47:37-41, 1974
18. Yamaguchi H, Furukawa K, Fortunato SR, et al: Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proc Natl Acad Sci USA 87:3333-3337, 1990
19. Livingston PO, Oettgen HF, Old LJ: Specific active immunotherapy in cancer therapy, in Mihich E (ed): Immunological Aspects of Cancer Therapeutics. New York, NY, 1982, pp 363-404
20. Livingston PO: Active specific immunotherapy in the treatment of cancer. Immunol Allergy Clin North Am 11:402-423, 1991
21. Portoukalian J, Zwingelstein G, Dore J: Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 94:19-23, 1979
22. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. J Natl Cancer Inst 78:45-54, 1987
23. Hamilton WB, Helling F, Lloyd KO, et al: Ganglioside expression on human malignant melanoma assessed by immune thin layer chromatography. Int J Cancer 53:566-573, 1992
24. Watanabe T, Pukel CS, Takeyama H, et al: Human melanoma antigen AH is an autoantigenic ganglioside related to GD2. J Exp Med 156:1884-1889, 1982
25. Pukel CS, Lloyd KO, Travassos LR, et al: GD3, a prominent ganglioside of human melanoma detection and characterization by mouse monoclonal antibody. J Exp Med 155:1133-1147, 1982
26. Tai T, Paulson JC, Cahan LD, et al: Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci USA 80:5392-5396, 1983
27. Furukawa K, Yamaguchi H, Oettgen HF, et al: Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies. Cancer Res 49:191-196, 1989
28. Yamaguchi H, Furukawa K, Fortunato SR, et al: Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 84:2416-2420, 1987
29. Welt S, Carswell EA, Vogel C-W, et al: Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 45:214-229, 1987
30. Jones PC, Sze LL, Liu PY, et al: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 66:249-254, 1981
31. Irie RF: Oncofetal antigen (OFA-I): A human tumor-associated fetal antigen immunogenic in man, in Rosenberg S (ed): Serological Analysis of Human Cancer. New York, NY, Academic, 1980, pp 493-513
32. Bell R, Torrigiani G (eds): Towards Better Carbohydrate Vaccines. New York, NY, Wiley, 1987, pp 1-363
33. Ritter G, Boosfeld E, Calves MJ, et al: Antibody response after immunization with gangliosides GD3, GD3 lactones, GD3 amide and GD3 gangliosidol in the mouse. GD3 lactone I induces antibodies reactive with human melanoma. Immunobiology 182:32-43, 1990
34. Ritter G, Livingston PO: Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol 2:401-409, 1991
35. Livingston PO, Koganty R, Longenecker BM, et al: Studies on the immunogenicity of synthetic and natural Thomsen-Friedenreich (TF) antigens in mice: Augmentation of the response by Quil A and SAF-m adjuvants and analysis of the specificity of the response. Vaccine Res 1:99-109, 1992
36. Helling F, Adluri S, Calves M, et al: Increased immunogenicity of GM2 conjugated with KLH and used with adjuvants in patients with melanoma. Proc Am Assoc Cancer Res 34:491, 1993 (abstr)
37. Helling F, Shang Y, Calves M, et al: GD3 vaccines for melanoma: Superior immunogenicity of KLH conjugate vaccines. Cancer Res (in press)